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INTRODUCTION 
Magnitude of Burden 
 
The population of India exceeds one billion and is projected to become the 
major reservoir of chronic diseases like diabetes and hypertension. With 25–40% 
of these subjects likely to develop ESRD the burden will rise. However, in the 
absence of any registry, data on incidence of ESRD in India do not exist.  
 
A figure of 100 per million population (pmp) per year is often cited, based 
on estimates from rest of the world, tertiary care center data, and collective 
experience of experienced Nephrologists39,40,41 Further, it has been estimated that 
less than 10% of all Indian ESRD patients receive any meaningful renal 
replacement therapy (RRT). 
 
The Solution- Treatment Strategies 
 
 Treatment option for End stage renal Disease-Stage5 (ESRD-stage5) 
patients are Haemodialysis, Peritoneal dialysis and Renal Transplantation.  
 Many studies proved that the kidney transplantation is distinctly superior 
and it is associated with reduced mortality and morbidity compared to 
haemodialysis or peritoneal dialysis3 – 16.  
z Renal donors for transplant are of three types:  
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{ live-related  
{ live-unrelated and  
{ cadaver 
z Most ESRD don’t have a suitable live-related donor for transplantation 
because of nuclear families, working members in the family and the 
increased prevalence of diabetes mellitus and hypertension among general 
population. The only option for them will be cadaver donors 
 
z The outcome of cadaver transplant is inferior to live-related and even live-
unrelated transplants 
 
z However 70% reduction in the overall mortality rate than when  
maintaining them on hemodialysis  
 
Most of the data for assessing transplant outcome is from United States 
Renal Database System (USRDS)1, Collaborative Transplant Study (CTS)2 
and Australia and New Zealand Dialysis and Transplant (ANZDATA) 
Registry.   
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Aim of the Study        4 
 
 To study the Outcome Of Graft Function With Reference To Cold 
Ischaemia Time In Cadaver Renal Transplant Prospectively 
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 ESRD 
 Factors affecting Graft Function 
 Cold Ischaemia time and its Impact 
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 Stages of  ESRD17 
Stage  Description GFR 
(ml/min/1.73m2) 
1  Kidney damage with normal or  GFR  >90 
2  Mild reduction in  GFR  60-89 
3  Moderate reduction in GFR  30-59 
4  Severe reduction in   GFR 
 
 15-29 
5  Kidney failure 
 
 <15 or dialysis 
Factors Affecting Renal Allograft Survival and Function 
 Prospective studies and analyses of registry data have shown that many 
factors are associated with renal allograft survival and function.  These can be 
considered as  
(1) Donor 
(2) Recipient, or  
(3) donor-recipient   
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Donor-Recipient Factors 
Delayed Graft Function 
 Defined as failure of the renal allograft to function immediately post-
transplantation, with the need for one or more dialysis sessions within a specified 
period, usually one week.  
 DGF is associated with poorer graft survival, poorer graft function, and 
higher risk of patient death10, in part because of the association of DGF with 
higher rates of acute rejection.  Rejection may be more common because 
ischemia-reperfusion injury increases the immunogenicity of the graft. 
 Most studies have also demonstrated that, even in the absence of 
documented acute rejection, DGF is associated with poorer long term graft 
function and survival11.   
 Risk factors for DGF are: 
¾ Donor age (>40 years) 
¾ Cold ischemia time (>12 hrs) 
¾ Recipient race  
¾ PRA (>50%) 
¾ HLA mismatch  
¾ Duration of dialysis 
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HLA Matching 
 Better HLA matched deceased donor allografts have better survival19 and 
function. So, many countries operate national or international sharing systems for 
zero-mismatched renal allografts, even though this prolongs cold ischemia time.  
The better outcomes are presumably related to fewer immunologic failures. 
However the benefits of HLA matching are diminishing, probably because of 
more effective immunosuppression19.  
Center Effect 
 Outcomes have varied widely among transplantation centers.  This reflects 
normal statistical variance as well as center expertise. Thus, between centers 
comparisons are difficult.  
Donor Factors 
 The quality of the kidney immediately prior to transplantation has a major 
impact on long term graft function and the risk of developing chronic allograft 
nephropathy. 
Donor Source: Deceased versus Living Donor 
 Most important predictors of short and long term graft outcomes.  In 
general, living donor grafts are superior to deceased donor grafts.  The better 
healthy living donors, the absence of brain death, the general benefits of elective 
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as opposed to semi emergency surgery, avoidance of ischemia-reperfusion injury, 
high nephron mass and probably the effects of a shorter waiting time.  Better 
compliance by the recipient in view of the relationship e.g., spouse, a care giver 
may also play a role.   
Donor Age 
 Deceased donor and living donor allografts from those aged older than 50 
years, and particularly older than 65 years, have poorer outcomes1.    Grafts from 
older donors have fewer functioning nephrons because of the aging process and 
donor-related conditions such as hypertension and atherosclerosis.   
Donor Sex 
 Grafts from deceased females’ donors have slightly poorer survival, 
particularly in male recipients1,21.  This probably reflects “nephron under dosing”, 
as females have smaller renal mass than males.  However, differences in the 
antigenicity of female grafts may also be a factor20. 
Donor Nephron Mass 
 An imbalance between the metabolic/excretory demands of the recipient 
and the functional transplant mass has been postulated to play a role in the 
development of chronic allograft nephropathy.  “Nephron under dosing”, 
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exacerbated by perioperative ischemic damage and postoperative nephrotoxic 
drugs, might lead to nephron overwork and eventual failure. 
Cytomegalovirus Status of Donor and Recipient 
 Small but definite effect of donor and recipient cytomegalovirus (CMV) 
serologic status on renal allograft and recipient survival1. Donor negative-
recipient negative-pairing have the best outcomes, whereas donor positive-
recipient negative pairing have the worst.  CMV probably affects graft outcomes 
via overt infection, but subclinical effects on immune function may also be 
important.    
Recipient Factors 
Recipient Age  
 In general, graft survival and function rates are poorer in those at the 
extremes of age: younger than 17 and older than 65 years1.  In the young, 
technical causes of graft loss such as vessel thrombosis are relatively more 
common.  Acute rejection is also common. 
 The elderly (those older than 65 years) have significant comorbid disease, 
particularly cardiovascular disease and type 2 diabetes mellitus.  Nevertheless, 
age per se is not a contraindication to transplantation: among elderly patients 
carefully screened and deemed fit for the procedure, long term outcomes are 
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clearly better with transplantation than dialysis3.  Conversely, acute rejection may 
be less common.   
Recipient Gender 
 Association of recipient gender with transplantation outcomes have yielded 
differing results.  In the CTS database2, female recipients had slightly better 
allograft survival than male recipients of deceased donor kidneys or HLA 
identical kidney21.  Females tend to be more sensitized because of pregnancy and 
possible because of more blood transfusions related to menstruation. 
Recipient Sensitization: before or after Transplantation 
 Patients who are broadly sensitized (e.g., panel reactive antibody [PRA] 
status >50%) at the time of transplantation generally have poorer early and late 
graft survival compared to nonsensitized recipients.  This is mainly related to an 
increased incidence of complications in the early post-transplantation period such 
as DGF and acute rejection.  The principal reasons for sensitization are previous 
transplants, pregnancy, and previous blood transfusions.  Highly sensitized 
patients are often given more intensive immunosuppression to reduce the risk of 
rejection, but this also exposes them to risk of infection and malignancy. 
 Presence of donor specific and nondonor specific HLA antibodies are 
associated with inferior graft survival22.  
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Recipient HCV Antibody and HBsAg  
 Recipients who are hepatitis C virus (HCV) antibody positive at the time of 
transplantation have poorer allograft survival and poorer survival1,24.  Higher 
mortality rates appear to be related to infection and worsening liver disease24.  
Nevertheless, transplantation of selected HCV positive patients confers a survival 
benefit as opposed to remaining on the dialysis27.   
 The adverse effects of hepatitis B virus (HBV) surface antigen positivity 
on post-transplantation outcomes are much less pronounced.   
Acute Rejection 
 Acute rejection has been consistently associated with an increased risk of 
graft loss.  This is due to irreversible graft injury at the time of acute rejection and 
probably ongoing subclinical immunemediated injury.  Acute rejection refractory 
to steroids, acute rejection where creatinine does not return near baseline, and late 
acute rejection (occurring after the first 6 months) are particularly associated with 
poorer graft and patient outcomes17.   
Recipient Immunosuppression 
 Tacrolimus was more effective than cyclosporine in preventing acute 
rejection and allograft loss but at the expense of higher rates of diabetes 
mellitus29. 
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 There is limited evidence that mycophenolate mofetil improves long-term 
graft survival both by preventing overt acute rejection and possible by other 
mechanisms. Significant level of cyclosporine and tacrolimus produces 30% 
increase in bioavailability of mycophenalate mofetil.  Short term studies of 
sirolimus have shown contradictory results30,31 
 Although antilymphocyte antibody preparations (e.g., antithymocyte 
globulin or interleukin-2 receptor blockers) are often used, particularly in the 
setting of DGF, their effects on long term graft survival and function have not 
been well studied.   
Recipient Compliance 
 Poor compliance with the immunosuppressive regimen is known to 
increase the risk of acute rejection, particularly late acute rejection, and chronic 
allograft dysfunction33 
Obesity 
 Obesity is associated with more DGF, higher mortality (related to 
cardiovascular complications), and poorer graft survival34. The poorer long term 
graft survival probably reflects the effects of DGF, nephron overwork, and more 
difficult dosing of immunosuppressive drugs. Transplantation in  patients with 
BMI >30 kg/m2  provides a survival benefit over remaining on the waiting list (on 
dialysis) at least up to a BMI of 41 kg/m2. 
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Recipient Hypertension: Angiotensin system 
 Greater the severity of post-transplantation hypertension is, the higher is 
the risk of graft loss35.  Hypertension could also be secondary to graft damage. 
No prospective human studies of the effect of treating hypertension on allograft 
outcomes are available.  However, control of hypertension is associated with 
improved allograft survival and function 36. 
 Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor 
blockers (ARBs) slow the progression of both diabetic and nondiabetic 
proteinuric native kidney disease.   
Recipient Dyslipidemia 
 Studies have suggested that hypercholesterolemia and/or 
hypertriglyceridemia are associated with poorer graft outcomes.  
 Recurrence of Primary Disease 
 Determining the incidence and prevalence of recurrent or de novo renal 
disease is difficult.  The cumulative incidence of graft loss at 10 years was 
8.4%37in glomerulonephritis.  Recurrence is the most important cause of loss, 
after chronic rejection and death 
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Proteinuria 
 The degree of proteinuria correlates with poorer renal outcome in both 
native and transplant kidney disease.  ACE inhibitors and ARBs has definite role 
in showing the progression of proteinuria in transplant renal disease.   
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Cold Ischaemia and Its Impact 
HISTORY OF COLD PRESERVATION  
The Early Days 
The first recorded attempt at perfusion of an isolated organ occurred in 
1849 by Loebel. In 1895, Langendorf devised a simple organ-perfusion 
technique.  
In 1937, Lindbergh and Carrel, fascinated with hypothermic preservation, 
created a perfusion apparatus. In 1953, Lapchinsky from the Soviet Union started 
successfully transplanting limbs and kidneys preserved at 4°C.  
In 1964, Belzer, while working with Najarian to develop a cadaver kidney 
transplant program at the University of California (San Francisco, CA), started to 
work on hypothermic perfusion techniques for the preservation of kidneys 
Collin’s Solution 
However, it was Collins et al. who first developed a simple yet effective 
cold storage solution in 1969. The solution contained a high concentration of 
glucose and electrolytes, mostly of intracellular composition. The seminal 
observation of Collins et al. that storage at 4°C after a simple perfusion can 
extend the viability of cadaver kidneys changed the practice of transplantation 
from an emergency procedure to a semielective one. 
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University of Wisconsin Solution 
Based on a series of attempts, Belzer and Southard in the early 1980s 
developed University of Wisconsin (UW) solution. A number of large-molecular-
weight cell impermeants were added to reduce tissue swelling. Glucose was 
replaced with phosphate buffers. On theoretical grounds, adenosine for rapid ATP 
repletion and glutathione (GSH) and allopurinol for antioxidant property during 
the reperfusion phase were added 
 
 
 
 
 
 
 
 
 
 
 18
Cold Ischemia Time -Definition 
 Cold ischaemia time is the time between cold perfusion of cadaver kidney 
in the harvesting centre till clamp release after anastomosis in Cadaver renal 
transplants.  
Cold Perfusion – Pros and Cons 
Organs for transplantation require effective ex vivo preservation from the 
moment the organ is retrieved to the time of transplantation. Hypothermic 
preservation solutions have been developed to maintain tissue viability by 
reducing metabolic activity and the accumulation of toxic substances during the 
cold ischemic period. In clinical renal transplantation, prolonged cold storage has 
been demonstrated in many studies to be strongly associated with delayed graft 
function (DGF)42-47 
Registry data suggest that >24 hours is particularly deleterious to the graft1. 
DGF results in complications in the immunosuppressive management of the 
transplant patient, prolonged hospitalization, and potentially detrimental effects to 
subsequent graft function and survival. 
Pathological Changes during Ischaemia 
There are at least four components to cold ischemic transplant injury:  
(1) the coupled effect of ischemia and hypothermia during cold storage  
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(2) the coupled effect of reperfusion and rewarming after transplantation. 
The effects of ischemia and reperfusion are widely studied, but the 
contribution of hypothermia and rewarming to them is difficult to separate 
and rarely studied 
Effects of Ischaemia- cellular level 
Ischemia favors the depletion of cellular adenosine nucleotides, alterations 
in membrane ATP-dependent ionic transporters, and the intracellular 
accumulation of Ca2+, Na+, and water.  
The great swelling of endothelial and tubular epithelial cells due to 
ischemia not only increases the acidosis caused by anaerobic oxidation, but also 
alters cell permeability and favors the obstruction of capillary flow. 
 Outer medullary vascular congestion is a prominent feature of ischemic 
acute renal failure and transplanted kidneys damaged during cold preservation of 
the grafts48 .  
The outflow of blood from the medulla during reperfusion is blocked49, 
limiting oxygenation of the tubule epithelial cells located in this region50.  
Reperfusion 
The process and mechanism of reperfusion injury of cold ischemic organs 
are likely similar to the reperfusion injury of warm ischemic organs, although no 
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direct comparison studies are available. The reperfusion of ischemic tissues also 
increases the release of intracellular enzymes, the influx of intracellular Ca2+. 
Free radicals and other reactive oxygen species that trigger T cell activation are 
produced after cold ischemia and rewarming during reperfusion.  
The increase in intracellular Ca2+ activates membrane phospholipase A2. 
The oxygen supplied by blood reperfusion generates free oxygen radicals, which 
react with lipid cellular membranes. The peroxidation of cell membrane lipids 
can disrupt the balance of vasoactive eicosanoid metabolism, leading to 
vasoconstriction due to excess thromboxane synthesis, and a decrease in the 
production of prostacyclin and prostaglandin I2.  
Endothelial Dysfunction , free radicals and cytokines 
The release of proteases, inflammatory cytokines, chemoattractants, and 
growth factors such as fibrogenic growth factor TGF-ß is also associated with 
upregulation of adhesion molecules and activation of leukocytes, macrophages, 
and monocytes in postischemic reperfused kidneys 
Endothelial cell dysfunction and activation of leukocytes contribute to the 
inflammatory process with the coordinated release of several cytokines and 
chemokines. Cold ischemic injury increases allograft immunogenicity, provoking 
acute and chronic rejections. Whether innate and adaptive immune responses play 
any key role in the process and whether the immune system within the allograft 
contributes to the injury process are of considerable interest51,52 
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Materials and Methods 
Place  
All cadaver renal transplants being carried out in Govt Stanley Medical   
College and Hospital are prospectively studied to assess the impact of 
variability in cold ischaemia on graft function in renal transplant recipient  
patients 
 
Period of Study 
October 2008 to April 2011  
 
Inclusion criteria 
All cadaver transplants first or second  
Criteria for Taking Up For Cadaver Transplant:  
¾ Patients with irreversible renal failure 
¾ Patients in cadaver waiting list 
¾ Dialysis dependent patients 
¾ Patients under the age of 50 years 
¾ Second Transplant patients 
¾ ABO compatible patients 
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Exclusion criteria 
Live related renal transplant  
Live unrelated renal transplant 
Non heart beating cadaver renal transplant 
Cadavers of less than 6 years 
Cadavers with creatinine of more than 2 
Cadavers with hypertension and Diabetics 
 
Design 
Prospective study 
Sample Size 
40 cadaver transplants 
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Procedure and Data Collection 
 
 Recipient’s demographic factors like Age, Gender, Occupation, and 
Literacy were noted. 
 Selection of recipients is based on their seniority in cadaver waiting list 
and cross match result. 
 All recipients were maintained on Haemodialysis. 
 All recipients were ABO compatible and cross-match negative and they are 
followed up regularly in our OP.  
 
 Human Leukocyte Antigen (HLA) and Panel Reactive Antibody (PRA) 
were not done to any of our recipients.   
 CMV status of the recipient was not checked routinely.  However, if any 
suspicion of CMV infection like hepatitis, leucopenia, etc., the CMV status 
of the recipient was checked with pp65 antigen and treated with 
Vangancyclovir if they were positive.     
 Graft function as assessed by serum creatinine within a week and first 
postop day urine output was the primary outcome analysed. 
 There were no drop outs from follow-up. 
 Donor kidneys were received from various hospitals in Tamil Nadu and 
from our own hospital.  
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 Donor’s age ranged from 15 – 60 years without evidence of kidney disease 
or any infection. 
 None of donors had diabetes mellitus or hypertension. 
 All the donors had negative serology (HBV, HCV, HIV). 
 All grafts were perfused with HTK solution (Custodial solution) 
 Custodial (HTK) solution (in mmol/L) 
• Sodium chloride     15.0 
• Potassium chloride      9.0 
• Potassium hydrogen 2-ketoglutarate    1.0 
• Magnesium chloride     4.0 
• Histidine Hcl        18.0 
• Histidine               180.0 
• Tryptophan        2.0 
• Mannitol      30.0 
• Calcium chloride              0.015 
 They are stored in ice box with three bag technique during transportation 
 Donor’s age, sex, cause of death, graft side and abnormality and 
biochemical profile were noted. 
 Transplant surgery was done by two teams of Urologists. 
 Ethical Committee approval from Stanley Medical College, Chennai was 
obtained for this study.  
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State Organ Coordinator and Organ Sharing 
All hospitals, approved for transplantation of human organs, and who are 
willing to participate in the arrangements for cadaver organ transplant program 
shall indicate their willingness to the Convenor, Cadaver transplant program, 
Tamil Nadu. 
All participating hospitals will upload details of their waiting list of 
prospective cadaver organ recipients through an online form to a computer 
database that will be maintained by the Transplant Coordinator of the 
Government General Hospital, Chennai.  
The database will maintain prioritization lists for 
(i) each hospital 
(ii) for all Government hospitals combined 
(iii) for all private hospitals combined and 
(iv)  for Government plus private hospitals combined, based on 
preset criteria determined in this order. 
The organ(s) of the brain dead patient shall be shared in the well discussed 
order, based on the respective prioritization list. 
Deceased Donor Graft Allocation Policy 
A separate cadaver waiting list for each blood group of potential recipients 
is maintained according to their date of induction into haemodialysis.  This 
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seniority list is available online .Recipients with co–morbid conditions are 
temporarily deleted from the list and included again once they recover. 
PROCEDURE  
Pre operative treatment 
 All recipients were given haemodialysis pre operatively.  They were started 
on immunosuppression prior to surgery as below. 
 
Drugs Day before Surgery 4 
p.m. 
0 POD (4 a.m.) 
T.Tacrolimus 0.066 mg/kg      0.066 mg/kg 
T.MMF 500 mg 500 mg 
T.Prednisolone 0.5 mg/kg 0.5 mg/kg 
 
Mode of preservataion and Transport 
Nephrology team would go to organ harvesting centre and would wait for 
the organ to be handed over after cold perfusion. Government officials including 
traffic controllers provided green channel route for speedy delivery of organ to 
the transplant centre 
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Receipient selection and preparation 
Prospective receipients of compatible blood groups from waiting list priority   
called for and blood investigations   be carried out. They also underwent dialysis. 
Negative crossmatch with donor (Lymphocytic microcytotoxicity) patient were 
selected for transplant 
Bench Dissection 
 
Received donor cadaver kidney was dissected further in bench dissection 
by clearing excess perinephric fat and ligating gonadal vessel and renal vein 
tributaries.  
Cadaver kidney was further perfused with HTK solution to preserve kidney 
from ischaemia and to avoid reperfusion injury. 
 
Operative Technique 
Under strict aseptic condition modified Gibson’s incision was made over 
anterior abdomen. Abdomen was entered extraperitoneally. Receipient bed was 
prepared by dividing the inferior epigastric vessels and delineating both external 
and internal iliac vessels. 
Anastomosis of the renal vessels to the iliac vessels was performed as 
follows. 
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Graft artery to internal iliac artery (end to end) or external iliac artery (end 
to side- and also in accessory artery anastomosis) using 6 ‘0’ prolene 
          Graft vein to external iliac vein – end to side using 6 ‘0’ prolene. Then 
clamps will be released. 
Ureterovesical anastomosis was done using 4’0’ vicryl. DJ stent (5 F 16 
cm) if any need was kept. DT will be kept. Abdomen was closed in layers.  
 During anastomosis of graft vessels, methyl prednisolone 1 g was given as 
I.V. infusion. 
Post operative treatment 
 Fluids (half normal NS) were given according to their urine output.  
Immunosuppression was given as follows: 
 T.Tacrolimus 0.066 mg/kg bd (Target tacro level 10 – 12 ng/ml 
subsequently reduced to 5ng/ml by 6 months) 
 T.MMF 500 mg bd 
 T.Prednisolone 0.5 mg/kg od 
 Tacrolimus levels were assessed on POD-5 for all recipients.  Doppler of 
graft vessels are assessed on POD-7.  Recipients urinary Foley’s Catheter was 
removed when urine output less than3litres.  Drainage tube was removed if 
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drainage fluid is less than 50 ml.  DJ stent was removed on 4th post operative 
week. 
 After 10 days, recipients were discharged and they were seen as outpatient 
at intervals of twice weekly for one month than weekly once for two months, 
thereafter fortnightly for one year and monthly for one year life long.  During 
each visit, patient’s condition, renal function test and complete blood count were 
analyzed.  Post operative drugs including immunosuppressants are given free of 
cost and all investigations are done at no cost.    
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Results 
 
40 patients received cadaver graft in our center from October 2008 to April 2011.  
Mean age of the recipients was 33.75 years.   
Among them males were 31 (77.5%) and 
 Female were 9 (22.5%). 
 
 
 
 
 
 
 
 
 
 
 
 
Nature of Disease 
Out of 40 patients one had ADPKD, one had biopsy proven IgA nephropathy and 
the remaining had contracted kidney for which native kidney biopsy was not 
done. The cause of chronic kidney disease for them is not known. 
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During the period of study, Diabetic patients were not included in the 
cadaver waiting list. All recipients were on antihypertensives.  One of the 
recipients was Hepatitis B positive. One was Hepatitis C positive.  None of the 
patients received induction therapy like ATG (Anti thymocyte globulin), 
Daclizumab or Basiliximab. 
Only one recipient had second transplant and all other had first transplant. 
All the recipients received tacrolimus, mycophenolate mofetil and prednisolone 
 
Graft side 
Left side graft  : 22 
Right side graft : 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
Left side Right side
Frequency
Percentage
 34
Graft 
 No anomaly      : 26 
 Vessel Anomaly     : 14 
  Renal vein anomaly   : 1 
  Renal artery anomaly   : 13 
 
 
 
 
 
 
 
 
 
 
 
 Management of Anomalous vessels 
Anomalous upper pole artery ligated  :8 
 Double anastomosis    : 5 
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Graft Function 
 Normal : 26 
 DGF  : 12 
Death : 2 
 
 
 
 
 
 
 
 
CIT and Graft Function 
CIT at 8hrs and below  : 21 
 Normal function  : 16 
 DGF    : 5 
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CIT above 8 hrs   : 17  
Normal function   : 10 
 DGF    : 7 
 
 
 
 
 
 
 
 
 
 
 
 
Per Op events 
 Uneventful    : 35 
 Mottling due to rejection : 1 
 Bleeding    : 2 
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Post op Complications 
Sepsis    : 2 
Nephrectomy due rejection : 1 
Leg ischaemia   : 1 
Pancreatitis    : 2 
Persistent DT   : 2 
Pneumonia    : 2 
Haematuria    : 1 
Fungal Sinusitis   : 1 
 
 
Death    n=10 
Post Op   : 2 
Delayed   : 8 
 
 
 
 
 
 
 
 
 
 
Death
Post Op  n=2
Delayed   n=8
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Post OP death – Cause 
Leg ischaemia  : 1 
DIC    : 1 
 
 
 
 
 
 
 
 
Delayed death 
Chronic Allograft Nephropathy    : 1 
HCV hepatitis      : 2 
Pneumonia       : 2 
DIC        : 1 
Sepsis       : 2 
 
 
 
 
 
 
Pos t Op  death
Leg  Ischaemia DIC
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
Cause
Chr allo
nephropathy
HCV hepatitis
Sepsis
DIC
Pneumonia
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Cause of Death – Cadaver 
CVA     : 2 
Fall from Height   : 8 
RTA     : 30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
Frequency Percentage
CVA
Fall
RTA
 40
 
 
 
 
Discussion        40 -49 
Cold ischaemia Time- the cadaver specific 
Newer Insights 
Baseline Characteristics 
General and Technical Factors 
CIT on graft function – continuous trend 
Harvesting centre (Transport) Vs CIT 
 
 
 
 
 
 
 
 41
DISCUSSION 
 
Cold Ischaemia Time - the cadaver  specific 
Although there has been a substantial improvement in the acute survival of 
renal allografts, the chronic allograft loss, particularly 
those from cadaveric donors, continues to occur at an unacceptably 
higher rate62 . The other parameter that has remained unchanged over the years is 
the CIT, which is again relevant to cadaveric kidneys. 
 
Donor factors such as brain death and CIT are unique to cadaveric donors, 
and their influence may account for much of the survival difference There is 
mounting evidence from experimental and clinical studies that the level of injury 
to organs from cadaver donors may be influenced by events occurring in the 
intensive care unit (ICU)55 and around the time of brain death56 , and that these 
may affect subsequent transplant outcome.  
 
Having been exposed to factors related to the dying process other 
influences will be added to the donor organ which will impact on the final 
outcome of transplantation. These will be related to the retrieval process itself 
and the subsequent period of cold ischaemia before reperfusion.  
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Finally, recipient factors will become active on reperfusion and for the 
lifetime of the graft. It is this blending of multiple donor and recipient factors that 
generates the final outcome of the transplant process. 
 
NEWER INSIGHTS INTO COLD ISCHEMIC INJURY MECHANISMS 
Although cold ischemic injury, as in warm ischemic injury, is considered 
to be due to massive cell necrosis, several recent studies suggest that the 
apoptotic form of cell death does occur, but only after the reperfusion of 
transplanted organs. Currently, suppressing apoptosis in the acute injury setting is 
considered beneficial. 
 
Permeability transition pore (PTP) 
Cold (top) via calcium and free radicals opens permeability transition pore 
(PTP), causing marked mitochondrial swelling, which, in turn, triggers key 
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apoptotic events and sets the stage for apoptosis during rewarming. Bcl-2 family 
of proteins, Bax, Bcl-XL, and Bcl-2, are particularly abundant at the junction 
between inner and outer mitochondrial membranes, which is the site where PTPs 
are formed and the site of membrane disruption during cold storage-rewarming. 
Bcl-2 counteracts the proapoptotic activity of the pore-forming Bax protein.  
Ratio of Bcl-2 to Bax 
Normally, the ratio of Bcl-2 to Bax is maintained in favor of Bcl-2, but 
during cold storage it is shifted toward Bax. Mitochondrial leakage of 
cytochrome c and other proapoptotic proteins such as Apaf-1 leads to the 
formation of apoptosome complexes composed of cytochrome c (cyt c), Apaf-l, 
ATP, and procaspase-9. Formation of the complex makes Apaf-I more competent 
at binding procaspase-9 and recruiting other caspases-1, -2, -3, and -4 through its 
recruitment domain (CARD), triggering the caspase cascade, the latter occurring 
during the rewarming phase after cold storage53,54 
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BASELINE CHARACTERISTICS OF RECIPIENTS 
 
No Characteristics Frequency Percentage 
 Gender 
 
1 
 
Male 31 77.5 
Female 9 22.5 
HT 40 100 
 
 
 
2 
Blood Group 
O positive 14 35 
B positive 15 37.5 
A positive 5 12.5 
AB positive 4 10 
B Negative 1 2.5 
A Negative 1 2.5 
 
3 
NKD 
ADPKD 1 2.5 
Unknown cause 38 92.5 
IgA Nephropathy 1 2.5 
 
5 
Graft side 
Left 22 55 
Right 18 45 
6 Anomaly 14 35 
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7 
I/II Transplant 
I 39 97.5 
II 1 2.5 
    
8 Immunosuppression 
Tacro + MMF+ 
Prednisolone 
40 100 
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General Factors 
¾ A single-centre study permits the use of data in a fairly homogeneous set 
and provides a useful complement to multi-centre studies. 
¾ In the major part of statistical analysis two post op deaths were excluded. 
¾ Like most studies, males predominated in the renal receipient group 
 
¾ Analyses of the datas were carried out by using EPI-INFO software.  
¾ Females in the receipient group were less in number (22.5%). So could not 
stratify the receipient into male and female group 
¾ Similarly the numbers in individual blood groups were minimal. So graft 
function vs blood group could not be carried out. 
¾ Age of the patient and tacro level did not appear to influence the graft 
function statistically. 
 
Technical Factors 
¾ Post-transplant serum creatinine as a marker of graft function is limited, as 
it varies by age, sex, race, and body weight. So first  
post -op day urine output is also taken to assess renal function. 
¾ In cadaveric allografts, DGF occurs in 20% to 50% of patients. DGF in this 
study (12/38) is well within this limit despite all logistical problems and 
financial strains of carrying the major surgery in the Government setup. 
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¾ The average CIT reported in the UNOS registry over the years has more or 
less remained unchanged around 20 hours. In the present study it is 8.3 hrs 
 
Cold Ischaemia Time-Chi Square Test 
CIT: 8hrs 
 Relative risk : 1.96(range 0.6 -3.5) 
 P value  : 0.14 
 
CIT: 9hrs 
 Relative risk: 2.4(range 1-6) 
 
CIT on graft function – continuous  trend 
CIT divided into 8 hrs, 8-10 hrs, more than 10 hrs and linear trend analysis of 
cold ischaemia time on graft function showed as cold ischaemia time increases 
the risk of delayed graft function increases 
 Odds ratio  : 2.9 
 P value : 0.05 
 
¾ CIT was the most significant risk factor for the development of DGF and 
its effect appears to be continuous. This observation is supported by other 
investigators57.  
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¾ Other studies have suggested that there are significant time points after 
which the risk of DGF accelerates58. It is attractive to imagine a specific 
threshold CIT after which the risk of DGF is significantly increased. 
However, it is clear that each hour even at short CIT adds additional risk.  
¾ Recent multi-centre studies have confirmed the importance of cold 
ischaemia time and donor age for graft survival. Su et al59 show that the 
effect is significant for times over 37 h compared with baseline. However, 
they do not test for discontinuity and overall, their data appear consistent 
with a continuous effect of CIT. The Collaborative Transplant Study60 
suggests that there is ‘little effect below 25 h’.  
 
Harvesting centre (Transport) Vs CIT 
¾ In US  reduction in CIT was observed during the 10-year period with an 
overall reduction of 4.8 hour ) with fewer kidneys being cold-stored over 
30 hour in the second half (13% in 1996 to 2000 vs 25% in 1990 to 1995, P 
< .001)61 .Initially kidneys were received from different corners of 
Tamilnadu by different transport .  
 
Cadaver kidney from different places n =11. 
 Average CIT was 10hrs 
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¾ Now majority of cadaver kidneys are from Government General Hospital 
and from  our institution Govt Stanley Hospital 
   n=29   
Average cold ischaemia time was 7.76hrs  
Clear reduction in CIT 
 
¾  Difficulty in deceased donor graft procurement, transport, delay in getting 
cross match results especially during odd hours and arranging theatre 
during odd hours are some factors accounting for variability in cold 
ischaemia time.  Over a period of time these are bound to improve 
 
 
 
 
 
 
 
 
 
 
 
 
 50
 
 
 
 
Conclusion        50 - 52 
Strength and limitation of the present study 
The Future 
 
 
 
 
 
 
 
 
 
 
 
 
 51
Conclusion 
Strength and limitation of the present study 
¾ The present study is limited as a result of failure to accurately assess renal 
core temperature and absence of continuous hypothermic machine perfusion 
which gives better and predictable perfusion than flushing the kidney with 
cold perfusion fluid and storing in hypothermic ice. 
 
¾ Despite these limitations, present analysis is important as it clearly shows 
Cold ischaemia time is the most significant risk factor for the development 
of DGF and its effect appears to be continuous. 
 
¾  Sharing of cadaveric kidneys at national level improves tissue matching, 
but often lengthens the cold ischemia time (CIT). 
 
The Future- Measures to improve renal allograft  function 
In future the following aspects could be evaluated and research would provide 
more possibilities 
 Preemptive transplantation in live kidney transplantation. 
 Increased donation from younger, previously healthy deceased donors. 
 Preferential matching of younger deceased donors with younger 
recipients. 
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 Zero mismatching of HLA antigens 
 Improved organ preservation 
 Reduced cold ischemia time 
 Nephron dosing (e.g. matching of donor recipient sex, body mass index) 
 Calcineurin inhibitor sparing immunosuppressive protocols. 
 Angiotensin converting enzyme inhibitors, angiotensin receptor 
blockers. 
 Aggressive control of hyperlipidemia, hypertension. 
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RECIPIENT PROFORMA 
 
Name:    Age:  Sex:  Blood Group: 
 
Address:      Occupation: 
 
 
Income:  Social Status:  Wt:  Ht:   BMI: 
 
Medical History: DM   Hypertension: 
 
Lab: 
 
Urea: 
 
Creatinine:    eGFR   NKD 
 
Sodium  Potassium  Bicarbonate   Chloride   
 
LFT  Serum Billurubin(T) D Alb Glob  SGOT 
SGPT  SAP 
 
Urine Routine:  24hrs urine Protein  Urine C/S 
 
HB  PCV  Platelets  TC  PT  aPTT 
 
INR 
 
BT  CT  FT4  TSH 
 
Calcium   Phosphorus   Uric acid 
 
Serology: HBsAg Anti Hcv   HIV  CMV 
 
ECHO   Gynecology   Dermatology 
 
Dental   ENT    MGE 
 
Urology   Endoscopy   Anesthesia 
 
 
 
Cross matching    USG 
Renal Biopsy    Chest X-ray   ECG 
On MHD Duration:   Weekly: 
H/o Blood Transfusion 
H/o access problem   Doppler iliac vessels: 
Date of Reg:   Date of Transplant:  Waiting time: 
Intra op events: 
Post op events: 
Post Transplant Outcome  
 
Immunosuppression 
 
 POD 1 POD 3 POD 5 POD 7 POD 1 
MON 
POD 3 
MON 
POD 6 
MON 
Creatinine        
Urine 
output 
       
 
Discharge Cr: 
 
Post Transplant Ultra sound / Doppler 
 
Tacro level      HB  PCV 
Platelets 
 
Biopsy      TC 
 
Urine routine 
 
24 hrs Urine Protein 
 
 
 
 
 
 
 
DONOR PROFORMA 
 
Name:    Age:  Sex:   
 
Address:      Occupation: 
 
       Blood Group: 
 
 
Income:  Social Status:  Wt:  Ht:   BMI: 
 
Cause of Brain death: 
 
Medical History: DM   Hypertension: 
 
Urea: 
 
Creatinine:     
 
Sodium  Potassium  Bicarbonate   Chloride   
 
LFT  Serum Billurubin(T) D Alb Glob  SGOT 
SGPT  SAP 
 
HB  PCV  Platelets  PT  aPTT  INR 
 
Serology: Anti Hcv  HBsAg  HIV  CMV 
 
Clinical: 
 
BP:  Pulse:  Ionotropic support: 
 
Urine Output: 
 
Clamp Time:  CIT:   Graft abnormality: 
Graft Side: 
 
USG KUB 
 
DOS: Donor Nephrectomy: 
 Date of Transplant: 
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1 Kondiaraj 32 M O+ 5.10% 25.10.08 23.1 1.7 1.6 1.4 CGN YES NO 36 N Lifeline NIL NIL 10 NEG N Radhakrishnan 49 M O+ NO NO LEFT 10 1 3 RA/CUFF RTA N DIED(18/1/10 CAN HTK T/M/P I 1500 CAN,sepsis Cr.1 wk :
2 Balaraman 32 M B+ 5.10% 21.11.08 22.2 1.6 1.2 1.1 CGN YES NO 12 LVH coimbat NIL NIL 8 NEG N Gnanaprakasem 26 M B+ NO NO LEFT 8 2 NIL RTA N DIED(20/1/10 NIL HTK T/M/P I 3400 HCV sepsis Cr.1 mon :
3 Bala krishnan 31 M B+ 5.10% 14.1.09 20.2 8.7 1.4 1.3 CGN YES NO 6 LVH apollo acc ligated HD-3 10 NEG N  Premkumar 48 M B+ NO NO LEFT 12 3 2RA RTA DGF ALIVE NIL HTK T/M/P I 390 Cr.6 mon :
4 Lilly Theresa 29 M B+ 5.10% 28.1.09 32.2 2 1.3 1.2 CGN YES NO 6 N apollo eeding,2RA liga NIL 3 NEG N Jeevarathinam, 56 F B+ NO NO LEFT 12 4 3RA RTA N ALIVE NIL HTK T/M/P I 4000 Intra OP :
5 SasiKumar 29 M A+ 5.10% 4.2.09 18.7 1 1.2 -- CGN YES NO 28 N Stanley acc to EIA NIL 16.3 NEG N  Suganya  15 F A+ NO NO LEFT 3 5 2RA RTA N DIED(9/4/9) NIL HTK T/M/P I 21000 CMV pneumonia,sepsis Post OP :
6 Baskar 38 M AB+ 5.10% 9.3.09 17.9 2.3 1.6 1.7 CGN YES NO 3 LVH SRMC NIL ACC.HT 10 NEG N  Asha 20 F AB+ NO NO LEFT 10 6 NIL RTA N DIED(15/6/9) HUS HTK T/M/P I 5750otic microangiopathy, graft rejecti Tacro level :
7 Dasan 48 M O+ 5.10% 14.3.09 25.6 4.2 4 1.6 ADPKD YES NO 24 N cmc NIL SEPSIS 2.9 HBV+ N  Jeyanthi Reddy 39 M O+ NO NO LEFT 10 7 NIL RTA DGF DIED(30/4/9) NIL HTK T/M/P I 5000 HCV sepsis(fungal) CIT :
8 Sakthivel 27 M B+ 5.10% 26.4.09 25.4 13.1 -- -- CGN YES NO 30 N apollo Mottling Nephrectomy 3.1 HCV+ N  Chandru 27 M B+ NO NO LEFT 10 8 NIL RTA DGF ALIVE NIL HTK T/M/P I 330 Tx - I/II :
9 Renuka 34 M B+ 5.10% 11.5.09 22.2 1.4 1 0.9 IgAN YES NO 48 N apollo Venous leak NIL 14.2 NEG N  Dharani 19 F B+ NO NO LEFT 7 9 NIL RTA N ALIVE NIL HTK T/M/P I 2125 CGN :
10 Xavier 43 M O+ 5.10% 21.6.09 25.8 -- -- -- CGN YES NO 24 N SRMC EIA Rt leg ischemia NEG N Sivaprakasam 42 M O+ NO NO LEFT 12 10 2 RA RTA DGF DIED(22/6/9) NIL HTK T/M/P I 350 postop, ischaemic leg ADPKD :
11 GopiKrishnan 40 M B+ 5.10% 8.8.09 22.1 3.1 1.2 1.3 FSGS YES NO 3 EF40% kamatchi Hilum anas  Hypotension 18 NEG N John rayan 57 m B+ NO NO LEFT 10 11 NIL RTA DGF ALIVE NIL HTK T/M/P I 3000 IgAN :
12 Subramani 48 M O+ 5.10% 15.10.09 19.5 0.9 0.9 0.8 CGN YES NO 48 N cmc NIL NIL 8 NEG N Vinoth Kumar 28 M O+ NO NO LEFT 11 12 NIL RTA N ALIVE NIL HTK T/M/P I 14800 LVH :
13 JayaKumar 30 M B- 5.10% 27.10.09 20.8 2.1 1.2 1.1 CGN YES NO 1 N GH NIL Pancreatitis 11 NEG N Iyyappan 28 M B+ NO NO RIGHT 10 13 NIL RTA N ALIVE NIL HTK T/M/P I 6370 RTA :
14 Eswaran 31 M B+ 5.10% 13.11.09 28.1 7.3 5.6 -- CGN YES NO 12 N GH Hypotension persistent DT 13 NEG N Loganathan 23 M B+ NO NO RIGHT 12 14 2 RV Fall from ht DGF
DIED
(7/6/10)
ACR/
AHR HTK T/M/P II 200
Nephrectomy,sepsis
T/M/P :
15 Prema 35 F A- 5.10% 4.12.09 31.2 7.4 1 1.2 CGN YES NO 24 LVH GH Hypotension Ionotropes 3.8 NEG N JaiAnand 18 F A+ NO NO LEFT 12 15 2 RA Fall from ht DGF ALIVE NIL HTK T/M/P I 800
16 Revathy 24 F O+ 5.10% 12.12.09 17.6 1.2 1.3 1.1 CGN YES NO 12 LVH GH NIL SEPSIS/ARDS 15 NEG N Palanivel 24 M O+ NO NO RIGHT 11 16 NIL RTA N ALIVE NIL HTK T/M/P I 17600
17 Devaraj 46 M O+ 5.10% 16.12.09 18.1 1.3 1.2 1.1 CGN YES NO 12 LVH GH NIL NIL 10.3 NEG N chandran 56 M O+ NO NO LEFT 11 17 NIL RTA N ALIVE NIL HTK T/M/P I 14000
18 Palani 37 M O+ 5.10% 27.12.09 19.3 1.6 1.4 1.2 CGN YES NO 24 LVH Stanley NIL NIL 15.2 NEG N Jayabharthi 15 F O+ NO NO LEFT 3 18 NIL RTA N ALIVE NIL HTK T/M/P I 14700
19 Elawarasan 22 M AB+ 5.10% 20.2.10 17.4 1 0.9 -- CGN YES NO 24 N GH NIL NIL 9 NEG N Vijay 12 M AB+ NO NO LEFT 5 19 NIL RTA N ALIVE NIL HTK T/M/P I 10400
20 Riyaz ali 25 M B+ 5.10% 27.2.10 18.9 0.9 0.8 0.8 CGN YES NO 12 N GH low p acc ligated NIL 12 NEG N Venkatasen 29 M O+ NO NO RIGHT 5.5 20 2 RA RTA N ALIVE NIL HTK T/M/P I 9650
21  Dass Prakash 31 M B+ 5.10% 19.3.10 26.6 1.6 1.2 1 CGN YES NO 6 N GH NIL NIL 10.9 NEG N Kuppan 45 M B+ NO NO RIGHT 10 21 NIL RTA N ALIVE NIL HTK T/M/P I 10000
22 Rajan 36 M B+ 5.10% 6.4.10 22.3 5.3 -- -- CGN YES NO 3 N GH NIL Fungal sinusitis 9.2 NEG N Malliga 34 F B+ NO NO RIGHT 8 22 NIL RTA DGF DIED(16/4/10 NIL HTK T/M/P I 300 Fungal sepsis
23 Devi   29 F O+ 5.10% 11.4.10 17.3 1.2 0.9 0.9 CGN YES NO 1 LVH GH NIL eumonia,Stitch absc 9.3 NEG N Lakshmi 45 F O+ NO NO RIGHT 9 23 NIL RTA N ALIVE NIL HTK T/M/P I 5300
24 Nirmala 34 F AB+ 5.10% 14.4.10 18.7 6.5 0.9 0.8 CGN YES NO 36 LVH Stanley NIL ATN 9.8 NEG N Rajadurai 19 M A+ NO NO LEFT 8 24 NIL Fall from ht DGF ALIVE NIL HTK T/M/P I 1500
25 Meramohiden 35 M O+ 5.10% 18.6.10 17.3 1 1.4 1.5 CGN YES NO 6 EF30% Stanley NIL 3.5 NEG N Rajarathinam 24 M O+ NO NO LEFT 6 25 NIL RTA N ALIVE NIL HTK T/M/P I 20000
26 Kumar 32 M A+ 5.10% 24.6.10 20.5 1.4 1.7 1.7 CGN YES NO 36 N GH low p acc ligated 11.2 NEG N Prabhakar 22 M A+ NO NO RIGHT 8 26 2 RA Fall from ht N ALIVE NIL HTK T/M/P I 6150
27 Kamaraj 43 M O+ 5.10% 01.7.10 19.8 3.5 1.9 1.3 CGN YES NO 8 LVH Stanley NIL left  pneumonia 3.5 NEG N Gaja 50 M O+ NO NO LEFT 5 27 NIL RTA DGF ALIVE NIL HTK T/M/P I 300
28 Abdul rahim 30 M AB+ 5.10% 04.7.10 16.3 1 1.1 0.9 CGN YES NO 24 LVH GH NIL 4.1 NEG N Ravikumar 29 M AB+ NO NO RIGHT 7 28 NIL RTA N ALIVE NIL HTK T/M/P I 12300
29 Nasir ali 25 M O+ 5.10% 15.7.10 27.2 7 2 1.2 CGN YES NO 7 N GH NIL 15.3 NEG N Ramesh 22 M O+ NO NO RIGHT 15 29 NIL Fall from ht DGF ALIVE NIL HTK T/M/P I 400
30 Amuthali 20 F B+ 5.10% 22.7.10 16.2 1.1 1.2 1.2 CGN YES NO 9 EF48% GH acc ligated persistent Dt ooze 5.1 NEG N Kasirajan 31 M B+ NO NO RIGHT 6.5 30 2 RA RTA N ALIVE NIL HTK T/M/P I 4650
31 Periasamy 29 M A+ 5.10% 13.10.10 17.5 4 1.5 1.3 CGN YES NO 36 N GH acc art toEIAad clot,scopy,evacuat 5.9 NEG N ThadaTherotti 20 M A+ NO NO RIGHT 6 31 2 RA RTA DGF ALIVE NIL HTK T/M/P I 7650
32 Arumugam 35 M A+ 5.10% 19.10.10 21.2 1.6 1.2 1.2 CGN YES NO 18 LVH Stanley NIL 5.6 NEG clot+ Mohan 25 M A+ NO NO RIGHT 8 32 NIL CVA N ALIVE NIL HTK T/M/P I 7550
33 Narasingam 23 M B+ 5.10% 30.10.10 17.4 6.8 1.2 1 CGN YES NO 42 N GH main EIA, acc IIA Pancreatitis 1 NEG N Desingh 32 M B+ NO NO LEFT 4 33 2 RA RTA N ALIVE NIL HTK T/M/P I 1725
34 Ramadoss 57 M B+ 5.10% 17.11.10 19.6 6.2 1.5 1.4 ADPKD YES NO 11 N GH NIL HD 9.6 NEG N Jyothi 60 F B+ NO NO RIGHT 8 34 NIL RTA DGF ALIVE NIL HTK T/M/P I 1620
35 Prakasam 40 M B+ 5.10% 6.12.10 19.2 CGN YES NO 6 N Stanley acc art toEIA _ NEG 35 M B+ NO NO LEFT 8 35 2 RA CVA _ DIED ATN HTK T/M/P I _ DIC
36 Suja 27 F O+ 5.10% 28.12.10 18.7 1.8 1 1.2 CGN YES NO 12 N GH acc art toEIA 5.1 NEG N Kali 23 M O+ NO NO RIGHT 8.5 36 2 RA Fall from ht N ALIVE NIL HTK T/M/P I 13000
37 Balaji 32 M O+ 5.10% 25.01.11 16.8 1.2 1.2 CGN YES NO 8 N GH NIL 6.8 NEG N Zegan 20 M O+ NO NO RIGHT 5 37 NIL RTA N ALIVE NIL HTK T/M/P I 18050
38 poonkodi 45 F B+ 5.10% 05.02.11 19.4 1.2 1.1 CGN YES NO 7 N GH low p acc ligated 11 NEG N Arun 22 M B+ NO NO LEFT 8 38 2 RA Fall from N ALIVE NIL HTK T/M/P I 9500
39 Sajeevan 34 M A+ 5.10% 09.03.11 18.3 1.1 1.1 CGN YES NO 10 N Stanley NIL 9.1 NEG N Sivaprakasam 33 M A+ NO NO RIGHT 5 39 NIL RTA N ALIVE NIL HTK T/M/P I 2520
40 Mather 32 M O+ 5.10% 27.03.11 26.3 1.1 1.1 CGN YES NO 9 N GH NIL 5.8 NEG N Jegadish 29 M O+ NO NO RIGHT 8 40 NIL Fall from N ALIVE NIL HTK T/M/P I 4330
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